Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record.

Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial

Open access
Salvarani, Carlo, Macchioni, PierLuigi, Manzini, Carlo, Paolazzi, Giuseppe, Trotta, Aldo, Manganelli, Paolo, Cimmino, Marco, Gerli, Roberto, Catanoso, Maria Grazia, Boiardi, Luigi, Cantini, Fabrizio, Klersy, Catherine, Hunder, Gene G. · 2007 · Annals of Internal Medicine

Abstract

BACKGROUND: A reliable alternative to steroids for treating polymyalgia rheumatica has not yet been identified. Although infliximab has been used occasionally in steroid-resistant cases, its efficacy has not been demonstrated in a controlled study. OBJECTIVE: To compare the efficacy of prednisone plus infliximab with that of prednisone plus placebo in patients with newly diagnosed polymyalgia rheumatica. DESIGN: Randomized, placebo-controlled trial. SETTING: 7 rheumatology clinics in Italy. PATIENTS: 51 patients with newly diagnosed polymyalgia rheumatica. Patients with associated giant cell arteritis and those who had been previously treated with steroids or biological or immunosuppressive agents were excluded. INTERVENTION: Initial therapy with oral prednisone tapered from 15 mg/d to 0 mg/d over 16 weeks according to a standard protocol, plus infusions of placebo or infliximab, 3 mg/kg of body weight, at weeks 0, 2, 6, 14, and 22. MEASUREMENTS: The primary efficacy end point was the proportion of patients without relapse or recurrence through week 52. Secondary outcomes were the proportion of patients no longer taking prednisone, the number of relapses and recurrences, the duration of prednisone therapy, and the cumulative prednisone dose. RESULTS: Four patients (3 in the infliximab group and 1 in the placebo group) did not complete the trial. The proportion of patients who were free of relapse and recurrence at 52 weeks did not differ between groups (6 of 20 patients [30%] in the infliximab group vs. 10 of 27 patients [37%] in the placebo group; adjusted risk difference, -3 percentage points [95% CI, -31 to 24 percentage points]; P = 0.80). In a sensitivity analysis that included dropouts, the best-case scenario yielded a difference of 5 percentage points (CI, -21 to 31 percentage points) between the groups. The secondary outcomes at weeks 22 and 52 did not differ between the groups. LIMITATIONS: The study had a small sample and a short follow-up. A low dosage of infliximab was used, and the prednisone dosage was rapidly tapered. CONCLUSIONS: Although too small to be definitive, the trial provides evidence that adding infliximab to prednisone for treating newly diagnosed polymyalgia rheumatica is of no benefit and may be harmful. If there is benefit, it is unlikely to be large. Australian Clinical Trials Registry number: ACTRN012606000205538.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-146-9-200705010-00005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 199

Metadata

Authors
Salvarani, C., Macchioni, P., Manzini, C., Paolazzi, G., Trotta, A., Manganelli, P., Cimmino, M., Gerli, R., Catanoso, M. G., Boiardi, L., Cantini, F., Klersy, C., & Hunder, G. G.
Venue
Annals of Internal Medicine
Published
2007-05-01
Volume
146
Issue
9
Pages
631-639
ISSN
  • 0003-4819
  • 1539-3704
OpenAlex
W2111122944
Cited by
199
References
0
FWCI
16.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-146-9-200705010-00005
The paper
Salvarani, C., Macchioni, P., Manzini, C., Paolazzi, G., Trotta, A., Manganelli, P., Cimmino, M., Gerli, R., Catanoso, M. G., Boiardi, L., Cantini, F., Klersy, C., & Hunder, G. G. (2007). Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-9-200705010-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.